Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RVPH | 8-K | bearish | 8/10 | Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid pr | May 13, 2026 |
| MBRX | 8-K | bullish | 6/10 | Moleculin Biotech announced preliminary blinded data from its pivotal Phase 2B/3 MIRACLE trial for Annamycin in relapsed | May 13, 2026 |
| IRWD | 8-K | mixed | 6/10 | IRWD CFO Gregory Martini resigned effective May 15, 2026, with Ronald Silver serving as interim CFO. The resignation is | May 13, 2026 |
| TARA | PRESS-RELEASE | neutral | 4/10 | Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash | May 13, 2026 |
| IPSC | PRESS-RELEASE | neutral | 4/10 | Century Therapeutics reported Q1 2026 EPS of -$0.11, beating the -$0.17 consensus by 35%, with zero revenue (in line). T | May 13, 2026 |
| SLXN | PRESS-RELEASE | bullish | 5/10 | Silexion Therapeutics announced initiation of GMP manufacturing of SIL204 with Catalent and ethics committee approval fo | May 13, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber announced an exclusive IP license agreement with BP United Inc. for autonomous drone technology, including | May 13, 2026 |
| TYRA | 8-K | mixed | 5/10 | Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R | May 13, 2026 |
| ALT | 8-K | neutral | 4/10 | Altimmune reported Q1 2026 results with a net loss of $0.18 per share, narrower than the $0.26 loss in Q1 2025, but the | May 13, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell announced the addition of Penn Medicine's Abramson Cancer Center as a clinical trial site for its pivotal Phase | May 13, 2026 |
| MIRA | 8-K | neutral | 3/10 | MIRA Pharmaceuticals announced the publication of a peer-reviewed manuscript on its preclinical drug candidate SKNY-1 in | May 13, 2026 |
| ABUS | 8-K | bullish | 7/10 | Arbutus reported Q1 2026 GAAP net income of $169.7M ($0.87 diluted EPS), a massive swing from a $24.5M loss in Q1 2025, | May 13, 2026 |
| ALT | PRESS-RELEASE | neutral | 5/10 | Altimmune reported Q1 2026 EPS of -$0.18, beating the -$0.25 consensus estimate by 28%, though revenue was $0 (vs $1K co | May 13, 2026 |
| ABUS | PRESS-RELEASE | bullish | 8/10 | Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat vs. consensus of -$0.06, driven by $178.7M in licen | May 13, 2026 |
| ABEO | PRESS-RELEASE | neutral | 5/10 | Abeona reported Q1 2026 net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025, with three patients treate | May 13, 2026 |
| KLRA | PRESS-RELEASE | neutral | 4/10 | Kailera Therapeutics and Hengrui Pharma announced two abstracts accepted for poster presentation at the ADA 2026 confere | May 13, 2026 |
| ABEO | 8-K | neutral | 5/10 | Abeona Therapeutics reported Q1 2026 net product revenue of $8.7M, up from $2.4M in Q4 2025, driven by three ZEVASKYN pa | May 13, 2026 |
| PVLA | 8-K | neutral | 2/10 | Palvella Therapeutics received approval from Nasdaq to transfer its common stock listing from the Nasdaq Capital Market | May 13, 2026 |
| MIST | 8-K | neutral | 5/10 | Milestone Pharmaceuticals reported Q1 2026 product revenue of $0.2M from its newly launched CARDAMYST, with ~600 scripts | May 13, 2026 |
| ALT | PRESS-RELEASE | bullish | 6/10 | Altimmune announced that its 48-week IMPACT Phase 2b data for pemvidutide in MASH has been selected for 'Best of EASL 20 | May 13, 2026 |
| MIST | PRESS-RELEASE | neutral | 5/10 | Milestone Pharmaceuticals reported Q1 2026 results with first-ever product revenue of $0.2M from CARDAMYST launch, but n | May 13, 2026 |
| UPB | PRESS-RELEASE | bearish | 6/10 | Upstream Bio reported Q1 2026 EPS of -$0.79, missing consensus of -$0.75 by 5.3%, with net loss widening to $40.6M from | May 13, 2026 |
| KMDA | PRESS-RELEASE | bearish | 7/10 | Kamada reported Q1 2026 EPS of $0.06, a 47.8% miss vs the $0.12 consensus, and revenue of $45.2M (+3% YoY) which was wel | May 13, 2026 |
| AVTX | PRESS-RELEASE | neutral | 6/10 | Avalo Therapeutics reported Q1 2026 results with a net loss of $19.6 million and GAAP EPS of -$0.98, in line with the co | May 13, 2026 |
| BYSI | PRESS-RELEASE | neutral | 4/10 | BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.4M, improved from a | May 13, 2026 |
| PDSB | PRESS-RELEASE | neutral | 5/10 | PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, dri | May 13, 2026 |
| HUMA | PRESS-RELEASE | mixed | 6/10 | Humacyte reported Q1 2026 revenue of $0.5M (vs $1.5M consensus) and EPS of -$0.13 (vs -$0.12 consensus), a miss on both | May 13, 2026 |
| CANF | 6-K | neutral | 4/10 | Can-Fite announced plans to advance its pancreatic cancer drug Namodenoson into a Phase 2b combination study with immuno | May 13, 2026 |
| ANRO | 8-K | mixed | 6/10 | Alto Neuroscience reported Q1 2026 results: net loss of $26.2M ($-0.80/share) vs $-15.2M ($-0.56/share) a year ago, with | May 13, 2026 |
| AVTX | 8-K | bullish | 8/10 | Avalo Therapeutics reported Q1 2026 results with a narrower-than-expected EPS loss of -$0.98 (vs consensus -$1.00) and h | May 13, 2026 |